查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961067

全球心血管器材市場：依器材類型、應用、最終用戶和地區劃分 - 市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Cardiovascular Devices Market: By Device Type, Application, End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球心血管器械市場呈現強勁成長勢頭，預計到 2025 年市場規模將達到 745.8 億美元。這一驚人的市場規模預計將在未來十年內增長近一倍，到 2035 年達到 1573.2 億美元。 2026 年至 2035 年預測期內的複合年增長率 (CAGR) 為 7.70%，反映了技術、監管和營運等多個領域多方面因素推動的強勁且持續的擴張。

推動市場快速成長的關鍵因素之一是脈衝場消融 (PFA) 和先進結構性心臟病治療等創新技術的引入。 這些創新治療方案正在改變心血管疾病的治療方式，為傳統手術提供創傷更小、更有效、更安全的替代方案。 這些技術的成功及其在臨床實踐中日益廣泛的應用，推動了全球對心血管器械需求的成長。

主要市場趨勢

心血管器械市場高度集中，少數幾家主要企業佔主導地位。美敦力、雅培、波士頓科學和愛德華生命科學等領導企業 擁有顯著的市場佔有率和影響力，引領著產業的創新和成長。這些公司正大力投資下一代科技的研發，尤其是在結構性心臟病解決方案、電生理學進展和人工智慧診斷工具方面。

身為市場領導者，美敦力擁有強勁的財務業績和成長。在2026財年第二季度，美敦力公佈的心血管相關收入為34.4億美元，實現了9.3%的強勁內生成長。這一顯著增長得益於Sphere-9脈衝場消融（PFA）系統和Evolut FX經導管主動脈瓣膜系統的成功推廣。

愛德華生命科學公司（Edwards Lifesciences）被公認為結構性心臟器材領域的領導企業，其業績表現強勁，2025年第二季銷售額達15.3億美元，年增11.9%。這一成長凸顯了市場對瓣膜治療（愛德華的核心業務）的持續需求。該公司持續的成功表明，結構性心臟介入治療在心血管器械市場中的重要性，並預示著專注於該領域的公司仍擁有持續的發展機會。

核心成長驅動因子

心血管疾病盛行率的不斷上升確保了心血管器械需求的長期持續增長。 僅在美國，預計到2030年將有約1210萬人被診斷患有房顫，這反映出受這種常見心律不整影響的人群顯著增加。 此外，截至2024年，美國約有1.279億成年人患有某種形式的心血管疾病，凸顯了這些疾病對公眾健康的廣泛影響。

新興機會與趨勢

基於人工智慧 (AI) 的診斷技術創新正在顯著擴大心血管器械市場，提高了疾病檢測和管理的準確性和效率。 AccuRhythm AI 等技術正在革新臨床醫生分析複雜心血管數據的方式，從而能夠更快、更準確地診斷心律不整和其他心臟疾病。這些人工智慧驅動的工具利用機器學習演算法和先進的資料處理技術，幫助醫療專業人員做出明智的決策，改善患者預後，並簡化臨床工作流程。

優化障礙

美國食品藥物管理局 (FDA) 和國際監管機構嚴格且耗時的審批流程對心血管器械市場構成了重大挑戰。 這些程序對於確保新臨床試驗和產品上市的安全性和有效性至關重要，但往往會導致創新產品上市時間延長。雖然這些法規對於保護病患健康至關重要，但其冗長的審批流程可能會減緩產業創新的步伐。這種監管環境對缺乏大型企業那樣雄厚資源和資金儲備的中小型企業的影響尤為顯著。

目錄

第一章 摘要整理：全球心血管器材市場

第二章 報告概述

  • 研究框架
    • 研究目標
    • 市場定義
    • 市場區隔
  • 研究方法
    • 市場規模估算
    • 質性研究
    • 量化研究
    • 依地區劃分的主要調查受訪者組成
    • 資料三角驗證
    • 研究假設

第三章 全球心血管器材市場概論

  • 產業價值鏈分析
    • 原料供應商（醫用金屬、聚合物等）電子元件）
    • 元件製造商（感知器、導管、導線、閥門）
    • 醫療器材製造商（支架、心律調節器、除顫器、心臟瓣膜）
    • 經銷商和醫療保健提供者（醫院、心臟中心、診所）
    • 最終使用者（心血管疾病患者、門診）
  • 行業展望
    • 心血管疾病盛行率上升及老化
    • 微創手術的普及
    • 科技趨勢（人工智慧驅動）（監測、穿戴式裝置、生物相容性材料）
    • 新興市場醫療基礎設施的擴張
  • PESTLE 分析
  • 波特五力分析
    • 議價能力供應商
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入估計與預測（2020-2035）
  • 市場吸引力分析
    • 依產品類型劃分
  • 可操作的洞見（分析師建議）

第四章 競爭格局概覽

  • 市場集中度
  • 公司佔有率分析（基於價值，2025 年）
  • 競爭格局分析與基準分析

第五章：全球心血管器材市場分析

  • 市場動態與趨勢
    • 成長驅動因素
    • 限制因素
    • 機遇
    • 主要趨勢
  • 市場規模及預測（2020–2035）
    • 依裝置類型劃分
    • 依應用程式劃分
    • 依最終用戶劃分
    • 依地區劃分

第六章：北美心血管器材市場分析

第七章：歐洲心血管器材市場分析

第八章：亞太地區心血管器材市場分析

第九章：中東和非洲心血管器材市場分析

第十章：南美洲心血管器材市場分析

第11章 企業簡介

  • Abbott
  • BIOTRONIK SE &Co. KG
  • Boston Scientific Corporation
  • Canon Medical Systems
  • B. Braun SE
  • Cardinal Health
  • Medtronic
  • LivaNova PLC
  • Siemens Healthcare GmbH
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • W. L. Gore &Associates, Inc.
  • Other Prominent Players

第12章 附錄

簡介目錄
Product Code: AA01261654

The global cardiovascular devices market is witnessing robust growth, with its valuation reaching USD 74.58 billion in 2025. This impressive market size is expected to nearly double over the next decade, with projections estimating it will reach USD 157.32 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 7.70% during the forecast period from 2026 to 2035, reflecting strong and sustained expansion driven by multiple factors across technological, regulatory, and operational domains.

One of the primary forces fueling this rapid market growth is the introduction of revolutionary technologies such as pulsed field ablation (PFA) and advanced structural heart therapies. These innovative treatment options are transforming how cardiovascular diseases are managed, offering less invasive, more effective, and safer alternatives to traditional procedures. The success and increasing clinical adoption of these technologies are contributing to heightened demand for cardiovascular devices globally.

Noteworthy Market Developments

The cardiovascular devices market is highly consolidated, with a handful of key players dominating the landscape. Leading companies such as Medtronic, Abbott, Boston Scientific, and Edwards Lifesciences hold significant market share and influence, shaping the direction of innovation and growth within the industry. These firms are heavily investing in the development of next-generation technologies, focusing particularly on structural heart solutions, electrophysiology advancements, and AI-powered diagnostic tools.

Medtronic stands out as the market leader, demonstrating strong financial performance and growth. In the second quarter of fiscal year 2026, Medtronic reported cardiovascular revenue of $3.44 billion, reflecting a robust 9.3% organic growth. This impressive expansion is largely attributed to the successful scaling of its Sphere-9 Pulsed Field Ablation (PFA) system and the Evolut FX transcatheter aortic valve system.

Edwards Lifesciences, recognized as a pure-play leader in structural heart devices, also showcased strong performance with $1.53 billion in sales for the second quarter of 2025, marking an 11.9% increase. This growth underscores the sustained demand for valve therapies, a core segment for Edwards. Their continued success highlights the critical importance of structural heart interventions in the cardiovascular devices market and signals ongoing opportunities for companies specializing in this area.

Core Growth Drivers

The rising prevalence of cardiovascular diseases guarantees a sustained and growing demand for cardiovascular devices in the long term. In the United States alone, it is projected that approximately 12.1 million people will be diagnosed with Atrial Fibrillation by 2030, reflecting a significant increase in the population affected by this common heart rhythm disorder. Furthermore, as of 2024, nearly 127.9 million US adults were living with some form of cardiovascular disease, underscoring the widespread impact these conditions have on public health.

Emerging Opportunity Trends

Innovation in artificial intelligence (AI)-based diagnostics is significantly expanding the cardiovascular devices market by enhancing the accuracy and efficiency of disease detection and management. Technologies such as AccuRhythm AI are revolutionizing the way clinicians analyze complex cardiovascular data, enabling faster and more precise diagnosis of arrhythmias and other heart conditions. By leveraging machine learning algorithms and advanced data processing, these AI-driven tools support healthcare professionals in making informed decisions, improving patient outcomes, and streamlining clinical workflows.

Barriers to Optimization

The rigorous and time-consuming approval processes imposed by the FDA and international regulatory bodies present significant challenges to the cardiovascular devices market. These procedures, which are essential to ensure the safety and efficacy of new clinical trials and product launches, often result in extended delays before innovative products can reach the market. While these regulations are critical for protecting patient health, the lengthy timelines involved can slow down the pace of innovation within the industry. This regulatory environment tends to disproportionately impact smaller firms, which may lack the extensive resources and capital reserves that larger companies possess.

Detailed Market Segmentation

By Device Type, the therapeutics and surgical devices category secured a commanding position within the cardiovascular devices market, capturing an impressive 77.5% share of total revenue. This strong dominance can be attributed to a significant transformation in medical practice, where there is a clear and growing preference for minimally invasive interventions over traditional open surgery. This shift reflects advancements in technology, improved patient outcomes, and a focus on reducing recovery times and associated risks.

By Application, the coronary artery disease sector held a dominant position within the global cardiovascular devices market, reflecting the ongoing critical importance of this medical condition. Coronary artery disease, a form of ischemic heart disease, continues to be the leading cause of death and disability worldwide. This persistent prevalence drives sustained demand for specialized cardiovascular devices designed to diagnose, treat, and manage the condition effectively.

By End User, hospitals stand out as the main purchasers of cardiovascular devices in today's market, serving as the central hub for acquiring and utilizing these critical medical products. Their role is particularly crucial because they manage the vast majority of emergency cardiovascular cases, including severe conditions like ST-Elevation Myocardial Infarctions (STEMI). Such emergencies demand swift and effective medical intervention, which in turn drives a substantial and urgent need for cardiovascular devices.

Segment Breakdown

By Device Type

  • Diagnostic & Monitoring
  • ECG
  • Holter Monitors
  • Event Monitors
  • Implantable Loop Recorders
  • Echocardiogram
  • Pet Scan
  • MRI
  • Cardiac CT
  • Doppler Fetal Monitors
  • Therapeutic & Surgical Devices
  • Pacemakers
  • Stents
  • Catheters and accessories
  • Guidewires
  • Cannulae
  • Electrosurgical Procedures
  • Valves
  • Occlusion Devices
  • Others

By Application

  • Cardiac Arrhythmia
  • Coronary Artery Disease
  • Heart Failure
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America maintains a strong and commanding presence in the global cardiovascular devices market, holding a substantial 45.68% share as of 2025. This prominent position is anchored by two main factors: significant localized demand and a highly developed healthcare infrastructure. In the United States alone, an estimated 127.9 million adults were managing cardiovascular conditions in 2024, creating an enormous and ongoing demand for cardiovascular devices. This large patient population ensures a steady and expanding market, as continuous treatment and intervention are necessary for effective disease management.
  • Additionally, the North American market, particularly the US, has seen a rapid and aggressive shift toward advanced, high-value cardiovascular therapies such as Pulsed Field Ablation (PFA). This innovative treatment approach has become a key driver of revenue growth in the region. For instance, Boston Scientific, a leading medical device company, generated over USD 1 billion in early revenue primarily due to the swift adoption of PFA technology within the US market. This rapid uptake highlights both the readiness of healthcare providers to embrace cutting-edge solutions and the region's capacity to support the commercialization of novel therapies, further solidifying North America's leadership in the cardiovascular devices sector.

Leading Market Participants

  • Abbott
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Canon Medical Systems
  • B. Braun SE
  • Cardinal Health
  • Medtronic
  • LivaNova PLC
  • Siemens Healthcare GmbH
  • Edwards Lifesciences Corporation
  • GE Healthcare
  • W. L. Gore & Associates, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Cardiovascular Devices Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Cardiovascular Devices Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers (Medical-Grade Metals, Polymers, Electronic Components)
    • 3.1.2. Component Manufacturers (Sensors, Catheters, Leads, Valves)
    • 3.1.3. Device Manufacturers (Stents, Pacemakers, Defibrillators, Heart Valves)
    • 3.1.4. Distributors & Healthcare Providers (Hospitals, Cardiac Centers, Clinics)
    • 3.1.5. End Users (Patients with Cardiovascular Diseases, Ambulatory Care Settings)
  • 3.2. Industry Outlook
    • 3.2.1. Rising Prevalence of Cardiovascular Diseases & Aging Population
    • 3.2.2. Increasing Adoption of Minimally Invasive Procedures
    • 3.2.3. Technology Trends (AI-Enabled Monitoring, Wearable Devices, Biocompatible Materials)
    • 3.2.4. Expansion of Healthcare Infrastructure in Emerging Markets
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Product Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Cardiovascular Devices Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Device Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Diagnostic & Monitoring
          • 5.2.1.1.1.1. ECG
          • 5.2.1.1.1.2. Holter Monitors
          • 5.2.1.1.1.3. Event Monitors
          • 5.2.1.1.1.4. Implantable Loop Recorders
          • 5.2.1.1.1.5. Echocardiogram
          • 5.2.1.1.1.6. Pet Scan
          • 5.2.1.1.1.7. MRI
          • 5.2.1.1.1.8. Cardiac CT
          • 5.2.1.1.1.9. Doppler Fetal Monitors
        • 5.2.1.1.2. Therapeutic & Surgical Devices
            • 5.2.1.1.2.1.1. Pacemakers
            • 5.2.1.1.2.1.2. Stents
            • 5.2.1.1.2.1.3. Catheters and accessories
            • 5.2.1.1.2.1.4. Guidewires
            • 5.2.1.1.2.1.5. Cannulae
            • 5.2.1.1.2.1.6. Electrosurgical Procedures
            • 5.2.1.1.2.1.7. Valves
            • 5.2.1.1.2.1.8. Occlusion Devices
            • 5.2.1.1.2.1.9. Others
    • 5.2.2. By Application
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Cardiac Arrhythmia
        • 5.2.2.1.2. Coronary Artery Disease
        • 5.2.2.1.3. Heart Failure
        • 5.2.2.1.4. Others
    • 5.2.3. By End User
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Hospitals
        • 5.2.3.1.2. Specialty Clinics
        • 5.2.3.1.3. Others
    • 5.2.4. By Region
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. North America
          • 5.2.4.1.1.1. The U.S.
          • 5.2.4.1.1.2. Canada
          • 5.2.4.1.1.3. Mexico
        • 5.2.4.1.2. Europe
          • 5.2.4.1.2.1. Western Europe
            • 5.2.4.1.2.1.1. The UK
            • 5.2.4.1.2.1.2. Germany
            • 5.2.4.1.2.1.3. France
            • 5.2.4.1.2.1.4. Italy
            • 5.2.4.1.2.1.5. Spain
            • 5.2.4.1.2.1.6. Rest of Western Europe
          • 5.2.4.1.2.2. Eastern Europe
            • 5.2.4.1.2.2.1. Poland
            • 5.2.4.1.2.2.2. Russia
            • 5.2.4.1.2.2.3. Rest of Eastern Europe
        • 5.2.4.1.3. Asia Pacific
          • 5.2.4.1.3.1. China
          • 5.2.4.1.3.2. India
          • 5.2.4.1.3.3. Japan
          • 5.2.4.1.3.4. South Korea
          • 5.2.4.1.3.5. Australia & New Zealand
          • 5.2.4.1.3.6. ASEAN
          • 5.2.4.1.3.7. Rest of Asia Pacific
        • 5.2.4.1.4. Middle East & Africa
          • 5.2.4.1.4.1. UAE
          • 5.2.4.1.4.2. Saudi Arabia
          • 5.2.4.1.4.3. South Africa
          • 5.2.4.1.4.4. Rest of MEA
        • 5.2.4.1.5. South America
          • 5.2.4.1.5.1. Argentina
          • 5.2.4.1.5.2. Brazil
          • 5.2.4.1.5.3. Rest of South America

Chapter 6. North America Cardiovascular Devices Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Device Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country

Chapter 7. Europe Cardiovascular Devices Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Device Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country

Chapter 8. Asia Pacific Cardiovascular Devices Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Device Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country

Chapter 9. Middle East & Africa Cardiovascular Devices Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Device Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country

Chapter 10. South America Cardiovascular Devices Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Device Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Abbott
  • 11.2. BIOTRONIK SE & Co. KG
  • 11.3. Boston Scientific Corporation
  • 11.4. Canon Medical Systems
  • 11.5. B. Braun SE
  • 11.6. Cardinal Health
  • 11.7. Medtronic
  • 11.8. LivaNova PLC
  • 11.9. Siemens Healthcare GmbH
  • 11.10. Edwards Lifesciences Corporation
  • 11.11. GE Healthcare
  • 11.12. W. L. Gore & Associates, Inc.
  • 11.13. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators